The Life Sciences Risk Map: Where Transparency Reporting Actually Breaks
Author
Ned Mumtaz is an international transparency reporting expert with extensive experience producing accurate and compliant transparency reports for over 150 pharmaceutical companies globally.
He has held leadership positions at Pfizer and Otsuka, distinguishing himself by ensuring high standards of accuracy, reliability, and regulatory compliance in reporting processes. He is recognized in the industry for his contributions to the development of global transparency models and for promoting operational best practices in compliance.
Cerchi supporto per la compliance al Sunshine Act?
Hai domande pratiche?
Dai un’occhiata alla nostra sezione Domande Frequenti per risposte chiare su scadenze, obblighi e strategie.
Transparency reporting blind spots are not always identified during program design. They can surface later during data reviews, reconciliation, audits, or after disclosures are published.
Ask a compliance officer where their transfer-of-value reporting program is most likely to break, and you’ll rarely hear “the regulation itself.” The regulatory and industry frameworks — including Italy’s Law 62/2022, the EFPIA Disclosure Code where applicable, and applicable data-protection requirements under the GDPR — are complex but knowable. What tends to catch companies off guard is everything sitting underneath the regulation: the entity that’s actually supposed to report, the quality of the HCP data feeding the disclosure, and whether the internal teams touching that data were ever actually coordinated.
Across transparency-reporting programs, three areas consistently deserve particular attention: entity attribution, HCP master data, and cross-functional governance.
Blind Spot One: Entity and Jurisdiction Ambiguity
Cross-border life sciences companies often operate through more than one legal entity in a single market, for example, a U.S. parent, a regional European entity, and/or a local subsidiary. Each carries different contracting authority, invoicing origin, and tax treatment. When contracts, invoices and payments involve different legal entities, determining which entity made the relevant transfer — and therefore how the transaction should be captured for transparency reporting — can require careful review. If that attribution is wrong, the underlying transaction value may be accurate while the reporting record is associated with the wrong entity.
Blind Spot Two: Incomplete or Fragmented HCP Master Data
A healthcare professional can exist as several slightly different records across a company’s CRM, medical affairs, and compliance systems, each capturing them for a different purpose. Without strong matching logic and sufficiently complete identity data, reconciling those records into one verified identity can become a manual, error-prone process. In Italy, this challenge is particularly relevant while the Sanità Trasparente infrastructure continues through implementation and testing.
Blind Spot Three: Uncoordinated Cross-Functional Ownership
In practice, transparency reporting often depends on inputs from compliance, legal, finance, IT, security, privacy and other functions. For example, when transaction data is generated in finance, recipient data is maintained in CRM or medical systems, and reporting decisions sit with compliance, gaps in ownership can create reconciliation work and inconsistent classifications. Reliable transparency reporting benefits from cross-functional ownership, clear policies and documented decision frameworks.
Why Mapping This Matters Before Sanità Trasparente Goes Fully Live
Once Sanità Trasparente is fully operational, reported disclosures will be publicly accessible through the register, which means any of these three blind spots- a misattributed entity, an unmatched HCP record, or a governance gap that let bad data through can become externally visible if it results in an incorrect disclosure. The companies best positioned for that moment are the ones treating entity clarity, master data quality, and cross-functional governance as three connected parts of the same risk map, not three separate projects handled by three separate teams on three separate timelines.
Transparency reporting blind spots are not always identified during program design. They can surface later during data reviews, reconciliation, audits, or after disclosures are published.
Ask a compliance officer where their transfer-of-value reporting program is most likely to break, and you’ll rarely hear “the regulation itself.” The regulatory and industry frameworks — including Italy’s Law 62/2022, the EFPIA Disclosure Code where applicable, and applicable data-protection requirements under the GDPR — are complex but knowable. What tends to catch companies off guard is everything sitting underneath the regulation: the entity that’s actually supposed to report, the quality of the HCP data feeding the disclosure, and whether the internal teams touching that data were ever actually coordinated.
Across transparency-reporting programs, three areas consistently deserve particular attention: entity attribution, HCP master data, and cross-functional governance.
Blind Spot One: Entity and Jurisdiction Ambiguity
Cross-border life sciences companies often operate through more than one legal entity in a single market, for example, a U.S. parent, a regional European entity, and/or a local subsidiary. Each carries different contracting authority, invoicing origin, and tax treatment. When contracts, invoices and payments involve different legal entities, determining which entity made the relevant transfer — and therefore how the transaction should be captured for transparency reporting — can require careful review. If that attribution is wrong, the underlying transaction value may be accurate while the reporting record is associated with the wrong entity.
Blind Spot Two: Incomplete or Fragmented HCP Master Data
A healthcare professional can exist as several slightly different records across a company’s CRM, medical affairs, and compliance systems, each capturing them for a different purpose. Without strong matching logic and sufficiently complete identity data, reconciling those records into one verified identity can become a manual, error-prone process. In Italy, this challenge is particularly relevant while the Sanità Trasparente infrastructure continues through implementation and testing.
Blind Spot Three: Uncoordinated Cross-Functional Ownership
In practice, transparency reporting often depends on inputs from compliance, legal, finance, IT, security, privacy and other functions. For example, when transaction data is generated in finance, recipient data is maintained in CRM or medical systems, and reporting decisions sit with compliance, gaps in ownership can create reconciliation work and inconsistent classifications. Reliable transparency reporting benefits from cross-functional ownership, clear policies and documented decision frameworks.
Why Mapping This Matters Before Sanità Trasparente Goes Fully Live
Once Sanità Trasparente is fully operational, reported disclosures will be publicly accessible through the register, which means any of these three blind spots- a misattributed entity, an unmatched HCP record, or a governance gap that let bad data through can become externally visible if it results in an incorrect disclosure. The companies best positioned for that moment are the ones treating entity clarity, master data quality, and cross-functional governance as three connected parts of the same risk map, not three separate projects handled by three separate teams on three separate timelines.
Author
Ned Mumtaz is an international transparency reporting expert with extensive experience producing accurate and compliant transparency reports for over 150 pharmaceutical companies globally.
He has held leadership positions at Pfizer and Otsuka, distinguishing himself by ensuring high standards of accuracy, reliability, and regulatory compliance in reporting processes. He is recognized in the industry for his contributions to the development of global transparency models and for promoting operational best practices in compliance.
Cerchi supporto per la compliance al Sunshine Act?
Hai domande pratiche?
Dai un’occhiata alla nostra sezione Domande Frequenti per risposte chiare su scadenze, obblighi e strategie.